3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
STARRY SEA ACQUISITION CORP disclosed that the redemption deadline for its Extraordinary General Meeting expired on October 15, 2026, with 3,895,270 public shares still tendered for redemption after 601,847 requests were withdrawn. The meeting, postponed to 9:00 a.m. Eastern Time on October 19, 2026, is the point at which these redemptions would be processed, so the figure bears directly on how many public shares remain outstanding.
Redemption deadline expired at 5:00 p.m. Eastern Time on October 15, 2026.
601,847 redemption requests were withdrawn as of the deadline.
3,895,270 public shares remain tendered for redemption, including requests received between October 7 and October 15, 2026.
The meeting was postponed from October 9 to 9:00 a.m. Eastern Time on October 19, 2026, to allow more time to engage with shareholders.
Apogee Acquisition Corp said errors in its June 30, 2026 quarterly report require a restatement of the financial statements, which should no longer be relied upon, with Amendment No. 1 to be filed October 16, 2026. The company also disclosed that director Anna Brunelle and COO Tom Watson have resigned, which affects board and officer staffing.
Errors involve the portion of private placement unit proceeds contributed to the trust account, plus the number of private placement units, Class A shares subject to redemption, and warrants.
Audit committee concluded on October 14, 2026 that the Q2 10-Q should be restated and no longer relied upon.
Anna Brunelle resigned from the Board, audit committee and compensation committee, effective October 13, 2026.
Tom Watson resigned as Chief Operating Officer, effective October 14, 2026; Christopher Valentine was appointed to the audit committee.
On October 16, 2026, the company filed prospectus supplements and entered agency agreements to continue or establish programs for Member Capital Securities, Medium-Term Notes, InterNotes and Retail Subordinated Notes. The filing sets up the framework for future sales of these securities but states no amounts sold, prices or proceeds, and it reports no financial results.
Four programs covered: Member Capital Securities, Series 2026; Medium-Term Notes, Series D; CFC InterNotes; and Retail Subordinated Notes.
Each program is described as an unlimited aggregate principal amount that may be offered from time to time.
Securities will be issued under a Form S-3 shelf registration filed October 14, 2026 (File No. 333-299452).
GoPro said its previously issued financial statements for fiscal 2025, the third quarter of 2025, and the first two quarters of 2026 should no longer be relied upon because of errors in accounting for debt instruments, including warrants issued to Mateo Financing and convertible debentures issued to YA II PN. The company identified a material weakness in internal control over financial reporting and plans to file restated amended reports. The filing says revenue, gross margin, operating loss, cash, and operating cash flows were not affected, but net loss was.
Audit Committee concluded on October 9, 2026 that the 2025 audited statements, the Q3 2025 statements, and the 2026 quarterly statements are materially misstated and should not be relied upon.
Warrant liability was understated, and long-term debt overstated, by $8.1 million at initial measurement on August 4, 2025.
Convertible debenture embedded conversion derivative of $30.9 million was initially recorded incorrectly, with the errors affecting interest expense and other income (expense).
Restated filings planned include a 2025 10-K/A, a Q1 2026 10-Q/A, and a Q2 2026 10-Q/A, with management's internal control report for 2025 also to be updated.
Conduent and two subsidiaries entered a class action settlement agreement on October 16, 2026, to resolve a consolidated lawsuit over the company's January 2025 cybersecurity incident. The settlement requires a non-reversionary $80 million fund and takes effect only if the U.S. District Court for the District of New Jersey approves it. The company says it maintains cyber insurance and does not expect a material impact on its financial position, results of operations or cash flows.
Company will fund $80 million into a non-reversionary settlement fund, its total monetary obligation under the agreement
Fund covers class member recovery, credit and medical data monitoring, plaintiffs' counsel fees and administration costs
Settlement releases the company, affected clients and their customers from claims tied to the cyber incident upon final approval
Agreement is not an admission of fault and remains subject to Court approval
On October 16, 2026, Cipher Digital issued $850.0 million of 0.00% convertible senior notes maturing November 1, 2032, with a 13-day option for initial purchasers to buy up to $150 million more. The company also entered capped call transactions costing about $89.7 million, which are expected to reduce potential dilution from conversions, and agreed to exchange about $165.9 million of its 2030 notes for about 40.7 million shares of common stock. The notes add debt and could dilute shareholders if converted, though the filing says the capped calls are expected to offset some of that dilution.
$850.0 million principal of 0.00% convertible senior notes due November 1, 2032; initial purchasers have a 13-day option for up to an additional $150,000,000
Initial conversion price of about $15.31 per share (65.3211 shares per $1,000 principal)
Capped call transactions cost about $89.7 million, with a cap price of $28.35, a 150% premium over the October 13, 2026 last sale price
Concurrent exchange of about $165.9 million of 1.75% 2030 notes for about 40.7 million shares of common stock
LifeStance Health Group disclosed that director Teresa DeLuca, M.D., notified the board on October 14, 2026, of her resignation from the board and all of its committees, effective December 31, 2026. The company states the resignation is not the result of any disagreement with the company.
Teresa DeLuca, M.D., resigns from the board of directors and all committees.
Resignation notified to the board on October 14, 2026, effective December 31, 2026.
Company states the resignation does not result from any disagreement with Dr. DeLuca.
Filing does not name a replacement director or describe any financial effect.
Enova International and Grasshopper Bancorp mutually terminated their December 2025 merger agreement on October 16, 2026. Enova made a $4,000,000 cash payment to Grasshopper, and neither party owes other fees or liabilities related to the agreement.
Merger agreement dated December 10, 2025, amended December 18, 2025, is now terminated effective October 16, 2026
Enova paid Grasshopper a $4,000,000 cash payment under the Mutual Termination Agreement and Release
No other fees or liabilities are owed by either party related to the merger agreement
Termination agreement is filed as Exhibit 10.1; General Counsel Sean Rahilly signed the report
Titan International entered a deferred compensation arrangement with CEO Paul G. Reitz worth $2.3 million, with payments not starting until 2030. The company funds the obligation by placing about 332,370 shares of common stock in an irrevocable rabbi trust, where assets remain subject to general creditors in insolvency.
Deferred compensation of $2.3 million awarded to CEO Paul G. Reitz under a plan approved by the Board on October 12, 2026
Payments will not begin until 2030, paid as a lump sum or installments as Mr. Reitz elects
About 332,370 shares, valued at approximately $2.3 million, will be contributed to the rabbi trust, which the Trustee votes
Trust assets remain subject to general creditors if the company becomes insolvent
SentinelOne completed a private offering of $1.25 billion of 0.00% convertible senior notes due October 1, 2031, with the $187.5 million over-allotment option exercised in full. The notes are unsecured and bear no regular interest, but they add debt, and conversion could dilute existing shareholders if the stock rises above the initial conversion price of about $31.21.
$1.25 billion of 0.00% convertible senior notes due October 1, 2031, including full exercise of the $187.5 million option
Initial conversion price of about $31.21 per share, a 30.0% premium over the $24.01 close on October 13, 2026
About $150.0 million of proceeds used to repurchase about 6.2 million Class A shares from note purchasers at $24.01 per share
Capped call transactions cost about $131.6 million, with a cap price of $48.02 per share, intended to reduce potential dilution
NRx Pharmaceuticals set December 17, 2026 as the date for its 2026 annual meeting of stockholders, which will be virtual-only, and October 28, 2026 as the record date for voting. The filing also sets revised deadlines for stockholder proposals and director nominations, which shareholders who want to act at the meeting need to meet.
2026 Annual Meeting: December 17, 2026, 10:00 a.m. Eastern Time, virtual-only by live webcast
Record date for stockholders entitled to vote: October 28, 2026
Rule 14a-8 proposal and advance notice deadline: close of business October 25, 2026
Universal proxy notice deadline under Rule 14a-19: October 26, 2026
XTI Drones Holdings, a subsidiary of XTI Aerospace, missed $1.5 million in principal payments due September 30, 2026 on two seller promissory notes tied to its Drone Nerds and Anzu Robotics acquisitions, triggering events of default on October 11, 2026. The defaults also create cross-defaults under the subsidiary's $20.0 million JPMorgan Chase credit agreement, which the company says may let the lender terminate commitments and accelerate about $8.4 million of outstanding revolving loans. The company says it does not have enough liquidity to repay all amounts that could come due, and that the situation could materially harm its liquidity and financial condition.
Missed payments: $1,380,000 under the DN Note and $120,000 under the AR Note, due September 30, 2026; events of default occurred October 11, 2026
Outstanding principal on the two notes is about $4.51 million as of October 11, 2026; default interest rate is 9.25% per annum
Credit agreement with JPMorgan Chase Bank, N.A. has about $8.4 million of revolving loans outstanding as of October 16, 2026; no remedy notice received yet
Company agreed in principle with sellers on a temporary waiver subject to a signed agreement; no assurance a deal will be reached
NioCorp said preliminary, unaudited results for the three months ended September 30, 2026 show net income attributable to the company of $3.7 million, or $0.03 per share, compared with a net loss of $42.7 million, or $0.53 per share, a year earlier. The company said the profit mainly reflects non-cash gains of about $8.5 million on liability-classified earnout shares and warrants, driven by a lower share price, and that its cash balance was $405.1 million at September 30, 2026.
Net income attributable to NioCorp of $3.7 million ($0.03 per share, basic) versus a net loss of $42.7 million ($0.53 per share) in the prior-year quarter
Non-cash gains of about $8.5 million on earnout shares and warrants classified as liabilities drove the result
Operating cash outflows of $6.1 million and investing outflows of $5.9 million in the quarter
Full unaudited quarterly financials are due in the Form 10-Q on or before November 16, 2026
The filing, which names Adial Pharmaceuticals, Inc. as the filer, says the company adjourned its 2026 Annual Meeting of Stockholders for a second time on October 15, 2026, for votes on Proposals 3, 4, 5 and 6. The company had not yet received Nasdaq's approval of its Initial Listing Application, which it submitted in connection with those proposals. Shareholders who already voted on those proposals need not act unless they want to change their vote.
Proposals 3, 4, 5 and 6 remain open; the meeting will reconvene on October 26, 2026, at 8:30 a.m. Eastern Time.
Proposals 1, 2, 7, 8, 9, 10, 11 and 12 were voted on at the September 17, 2026 session.
Nasdaq approval of the Initial Listing Application was still pending as of October 15, 2026.
The record date remains August 17, 2026, and no changes were made to the proposals.
On October 14, 2026, Silver Bow Mining's board approved a grant of 2,000,000 performance warrants to CEO C. Travis Naugle, subject to NYSE American and any required shareholder approval. The board also amended 200,000 existing performance warrants, replacing a preliminary economic assessment milestone with milestones tied to the pending Jefferson County Metallurgical Complex acquisition and a term sheet with Ocean Partners UK Limited.
New warrants allow purchase of up to 2,000,000 common shares, with exercise prices of $12.00 for four milestones and $18.00 for the production milestone
The grant date will be the date shareholders approve the new warrants under NYSE American rules; no shares may be issued before then
Montana Tunnels milestones, including the September 8, 2026 initial closing of the Jefferson County acquisition and the September 21, 2026 term sheet, were deemed achieved as of October 2, 2026
The term sheet provides for a potential funding and credit support package of approximately $88 million
On October 8, 2026, Mobix Labs held an investor call on its critical minerals strategy, with the transcript furnished as Exhibit 99.1 to this Form 8-K. The company said fiscal fourth-quarter 2026 revenue, which ended September 30, is now expected to come in closer to the high end of its $1.4 million to $1.8 million guidance range, and that growth is expected to continue into fiscal first quarter 2027. The call also covered the planned acquisition of Special Project Delivery, which has agreed to acquire Winner Water Services, and the filing states that each transaction has its own closing conditions and approval requirements.
Fiscal Q4 2026 revenue is expected closer to the high end of the $1.4 million to $1.8 million guidance range, well above the $1.6 million midpoint.
The company said this would represent more than 100% growth quarter over quarter, with substantially higher gross margins.
Winner Water Services has received $53 million in Department of Energy and Department of Defense awards over ten years and is building a $25 million demonstration plant in Alabama, with operations expected no later than Q1 2028.
CEO Phil Sansone said he could envision a $30 to $50 million revenue run rate at this time next year, a forward-looking view rather than formal guidance.
Apollo Commercial Real Estate Finance, Inc. said it has notified the NYSE of its intent to voluntarily delist its common shares, with the last trading day expected on November 6, 2026. After delisting, the company plans to transfer its remaining assets and liabilities to a Maryland liquidating trust, distribute trust interests to stockholders one-for-one, and deregister with the SEC around November 9, 2026. Those trust interests will not be transferable or trade on any exchange, so shareholders will lose a market for their holdings.
Form 25 filing to remove the shares from NYSE listing expected on or about October 27, 2026
Last day of trading on the NYSE expected to be November 6, 2026
Company expects to deregister with the SEC on November 9, 2026
Beneficial interests in the Liquidating Trust distributed one-for-one to stockholders; they will not trade on the NYSE or any other exchange
Iambic Therapeutics filed an amended and restated certificate of incorporation and adopted amended and restated bylaws on October 16, 2026, in connection with completing its initial public offering. The filing refers to the prospectus filed October 15, 2026 for the full description of the new governing documents, which set out the company's shareholder framework now in effect.
Restated Certificate of Incorporation filed with Delaware Secretary of State on October 16, 2026, tied to the IPO completion
Restated Bylaws adopted effective October 16, 2026, described in the October 15, 2026 final prospectus
Item 7.01 notes the company may use its website, social media and other channels to disclose material information
Bridgeline Digital received a Nasdaq letter stating its common stock has not maintained the $1.00 minimum bid price for 30 consecutive business days ended October 13, 2026. The company has until April 12, 2027 to regain compliance by closing at or above $1.00 for at least ten consecutive business days, and the letter does not trigger immediate delisting. Shareholders should note that failure to regain compliance could lead to further Nasdaq action.
Nasdaq letter received October 14, 2026, citing Listing Rule 5550(a)(2) minimum bid price of $1.00 per share
Compliance deadline is April 12, 2027, a 180-calendar-day Initial Compliance Period
Company may be eligible for an additional 180-calendar-day period if it meets other listing standards and gives written notice of intent to cure
Letter does not result in immediate delisting from The Nasdaq Capital Market
NioCorp's majority-owned subsidiary Elk Creek Resources signed an Offtake Agreement with Traxys North America on October 13, 2026, replacing prior ferroniobium and scandium offtake agreements with Traxys. The deal gives Traxys take-or-pay purchase rights on 50% of annual ferroniobium output and exclusive marketing rights for 100% of other Elk Creek products, which matters to shareholders because it sets the sales framework for the project's planned output.
Agreement dated October 13, 2026, between Elk Creek Resources and Traxys North America LLC
Traxys to buy 50% of annual ferroniobium production on a take-or-pay basis, or 3,700 metric tonnes per year at Traxys' election
Term of 15 years from the Commercial Production Date, followed by two automatic one-year renewals
Either party may terminate if the Export-Import Bank of the United States has not given final approval of senior debt financing by December 31, 2027
High Roller Technologies said its Audit Committee concluded on October 15, 2026 that its unaudited financial statements for the quarters ended March 31 and June 30, 2026 should no longer be relied upon. The error involved approximately $1.0 million of warrant costs tied to a January 2026 registered direct offering; the correction is non-cash, does not affect revenue or cash, and would reduce the reported net loss, but the company also identified an additional material weakness in internal control over financial reporting. The company intends to file amended Forms 10-Q on October 16, 2026.
Q1 2026 net loss restated to $2.0 million, or $0.19 per share, from $3.0 million, or $0.29 per share
Six-month net loss through June 30, 2026 restated to $4.3 million, or $0.41 per share, from $5.3 million, or $0.50 per share
Approximately $1.0 million of warrant grant-date fair value was wrongly expensed as G&A instead of reducing additional paid-in capital
Amended 10-Q reports to be filed October 16, 2026; WithumSmith+Brown was briefed on the matters
Canopy Growth received a Nasdaq letter dated October 14, 2026, saying its common shares have traded below $1.00 for 30 consecutive business days. The Letter has no immediate effect on the Nasdaq listing, and the company has until April 12, 2027 to regain compliance, with a possible reverse stock split proposed to shareholders at an October 23, 2026 reconvened meeting.
Nasdaq Letter dated October 14, 2026 cites Listing Rule 5450(a)(1) minimum bid price requirement of $1.00 per share
Compliance period runs 180 calendar days to April 12, 2027; shares must close at or above $1.00 for at least ten consecutive business days
Share Consolidation Proposal would allow a ratio of one new share for every five to 15 old shares, set by the board, before October 23, 2027
Annual Meeting reconvenes Friday, October 23, 2026 after a lack of quorum on September 25, 2026; the company states no assurance of approval or price increase
IonQ entered into an underwriting agreement on October 14, 2026 with J.P. Morgan Securities LLC for a sale of 20.5 million common shares, 29.5 million pre-funded warrants and 100 million Series C warrants, with each share or pre-funded warrant offered with two Series C warrants at a combined price of $40.00. The offering closed on October 16, 2026. The filing shows the new shares and warrants add potential dilution for existing shareholders, and the Series C warrants can be exercised at $69.46 per share for up to seven years.
Offering closed October 16, 2026, after an underwriting agreement dated October 14, 2026 with J.P. Morgan Securities LLC as sole underwriter
Offered 20.5 million common shares and 29.5 million pre-funded warrants, each paired with two Series C warrants, at a combined price of $40.00
Series C warrants total 100 million, with an exercise price of $69.46 per share and a term through the seven-year anniversary of issuance
Warrants were issued under agreements dated October 16, 2026 with Continental Stock Transfer & Trust Company as warrant agent
PharmaCyte Biotech's Audit Committee dismissed CBIZ CPAs as its independent registered public accounting firm on October 14, 2026, and engaged Grassi & Co., CPAs as its replacement. The filing reports no adverse or qualified audit opinions from CBIZ CPAs for fiscal 2026 and 2025, but it discloses material weaknesses in internal control tied to segregation of duties of the Chief Financial Officer and management review controls.
Dismissal of CBIZ CPAs effective October 14, 2026; CBIZ CPAs' reports for fiscal years ended April 30, 2026 and 2025 contained no adverse opinion, disclaimer, or qualification
Grassi & Co. approved October 14, 2026 to audit fiscal year ending April 30, 2027 and review interim statements starting with the quarter ending October 31, 2026
Disclosed material weaknesses relate to insufficient segregation of duties of the Chief Financial Officer and insufficient management review controls
CBIZ CPAs letter dated October 16, 2026 filed as Exhibit 16.1
TuHURA Biosciences borrowed an additional $650,000 on October 9, 2026, under a revolving credit facility with Parkview Holdings One LLC, as disclosed in a Form 8-K filed October 16, 2026. The company said it expects to use the funds for general corporate purposes, and the draw is small relative to the $50 million maximum availability under the facility.
Draw of $650,000 received and borrowed on October 9, 2026
Revolving credit facility under Loan Agreement dated April 21, 2026, with a maximum loan availability of $50 million
Facility matures April 21, 2031; the company expects to use funds for general corporate purposes
Filing notes risks including potential conflicts of interest from the loan with an affiliate of the largest stockholder
On October 16, 2026, Mary Szela resigned from the board of Averin Capital Acquisition Corp. and from its audit and compensation committees, effective the same day, and the filing says the resignation was not due to any disagreement with the company. The board filled the open seats by naming Graeme Bell as compensation committee chairperson and Akiko Moni Miyashita as an audit committee member, both effective October 16, 2026.
Mary Szela resigned from the board, the audit committee and as chair of the compensation committee, effective October 16, 2026.
The filing states her resignation was not the result of any disagreement with the company on operations, policies or practices.
Graeme Bell was appointed compensation committee chairperson and Akiko Moni Miyashita was appointed to the audit committee, both effective October 16, 2026.
Waterstone Financial, Inc. said director Derek L. Tyus resigned from the boards of the company and WaterStone Bank SSB, effective October 20, 2026, citing a new professional commitment. The filing states the resignation did not result from any disagreement with the company or bank on operations, policies or practices.
Derek L. Tyus resigned from the Boards of Directors of the Company and the Bank, effective October 20, 2026.
Tyus joined the boards in 2021 and served on the Audit and Compensation Committees of the Company Board and the Bank Board's Executive Committee.
The company said the resignation was due to a new professional commitment and was not the result of any disagreement.
Chairman Patrick S. Lawton thanked Tyus for his service in the press release.
Live Nation closed private offerings of $730 million of 7.125% U.S. dollar senior notes and €600 million of 6.125% euro senior notes, both due 2032, and plans to use the proceeds to redeem its 6.500% senior secured notes due 2027. The company also amended its senior secured credit facilities, extending their maturity by one year to October 21, 2031 and increasing several commitments, which shareholders may watch as the company's debt structure changes.
Notes closed October 15, 2026: $730 million at 7.125% and €600 million at 6.125%, both maturing October 15, 2032.
Proceeds are intended to fund full redemption of the 6.500% senior secured notes due 2027, plus fees, expenses and general corporate purposes.
After cross-currency swaps, the weighted average interest rate on the notes is approximately 5.89% per annum, compared with 6.500% on the notes being redeemed.
Credit agreement amendment extends revolving and delayed draw term loan A maturities to October 21, 2031, with commitments of $1,450 million, $435 million and $725 million.
Costco's board committees approved fiscal 2027 bonus criteria for executive officers, tying payouts to sales, pre-tax income and environmental and social metrics. The filing sets base bonus amounts for the CEO and other executive officers, with payouts scaling by performance.
CEO base bonus of $1.2 million for fiscal 2027, split $500,000 on sales targets and $500,000 on pre-tax income targets, plus up to $200,000 on environmental and social metrics
Other executive officers have base bonuses of $400,000, split $160,000 on sales and $160,000 on pre-tax income, plus up to $80,000 on environmental and social objectives
Each financial goal can pay from zero up to 120% of target; criteria approved October 13, 2026
Eaton filed a Form 8-K on October 16, 2026 to recast segment information in its 2025 Form 10-K, combining the legacy Vehicle and eMobility segments into one Mobility segment after a first-quarter 2026 reorganization. The company says the changes are not a restatement of its financial statements, and the filing does not update results or events after the original 10-K. For shareholders, this changes how segment results are presented rather than reporting new performance.
Exhibit 99.1 recasts Items 1, 7, 8 and 15 of the 2025 Form 10-K, which was originally filed February 26, 2026
Vehicle and eMobility segments are combined into a new Mobility segment, effective with the reorganization in the first quarter of 2026
The filing states it does not amend or restate the audited 2025 financial statements; the auditor's report is dual-dated October 16, 2026
Kingstone Companies (KINS) said it will release third quarter 2026 financial results after the market closes on November 5, 2026, followed by a conference call on November 6, 2026 at 8:30 a.m. ET. The filing is a scheduling notice and contains no financial results, so it does not indicate how the quarter performed.
Third quarter 2026 results release after market close on Thursday, November 5, 2026
Conference call at 8:30 a.m. ET on Friday, November 6, 2026; U.S. toll-free dial-in 1-877-407-2991
Replay of the webcast to remain accessible for approximately 30 days after the call
Alector, Inc. agreed on October 15, 2026 to sell 36,600,000 new shares of common stock at $2.05 per share through underwriters Morgan Stanley and BTIG, with expected gross proceeds of $75,030,000 before underwriting discounts and offering expenses. The offering is expected to close on October 19, 2026, and the company plans to use the net proceeds for general corporate purposes, including research, development and manufacturing. Because the company is issuing new shares, existing shareholders will own a smaller percentage of the company after closing.
Pricing: 36,600,000 shares at $2.05 per share, a premium of about 7.3% over the October 15, 2026 closing price
Expected gross proceeds of $75,030,000 before underwriting discounts and offering expenses
Expected closing on or about October 19, 2026, subject to customary conditions
Underwriters are Morgan Stanley & Co. LLC and BTIG, LLC; the offering is made under an effective Form S-3 shelf registration
CalciMedica's Chief Financial Officer, principal accounting officer and principal financial officer, Stephen Bardin, gave notice of his resignation on October 15, 2026, to pursue another professional opportunity. The resignation takes effect immediately after the company files its Form 10-Q for the quarter ended September 30, 2026, and the company said it was not due to any disagreement.
Stephen Bardin is CFO, principal accounting officer and principal financial officer.
Notice given October 15, 2026; effective immediately after the Q3 2026 Form 10-Q is filed.
Resignation is to pursue another professional opportunity, and the company states no disagreement was involved.
The filing names no successor or interim financial officer.
TScan Therapeutics disclosed that directors Garry Nicholson and Gabriela Gruia, M.D., resigned from its Board of Directors and all board committees, effective October 13, 2026, with no disagreement with the company cited. The board filled the vacancies on its committees, appointing Stephen Biggar and R. Keith Woods to the Nominating and Corporate Governance Committee, which matters to shareholders as a change in board composition and committee makeup.
Garry Nicholson and Gabriela Gruia, M.D., resigned from the board and all committees effective October 13, 2026.
The filing states the resignations were not due to any disagreement with the company on operations, practices or policies.
Stephen Biggar (member) and R. Keith Woods (chairperson) were appointed to the Nominating and Corporate Governance Committee effective October 13, 2026.
The Audit Committee now consists of Katina Dorton, Barbara Klencke and R. Keith Woods.
CID HoldCo agreed on October 9, 2026 to cancel about $368,107 in loans from its CEO, CFO/COO and CTO. In exchange, the company will pay about $37,075 in cash and issue 55,613 shares at a deemed price of $6.00 per share, and it has committed to issue 752,889 more shares to other creditors. The deal removes debt but adds new shares that can be sold after the April 15, 2027 lock-up ends, and the filing says it was approved as a related person transaction.
Executive loans totaled $368,107.25 as of October 9, 2026, including principal and unpaid interest.
Settlement terms: about $37,075 cash (roughly 10% of the debt) plus 55,613 shares at a deemed price of $6.00 per share.
As of October 15, 2026, the company committed to issue 752,889 shares to other creditors on similar terms.
Shares are locked up through April 15, 2027; the cash payment is due by December 31, 2026, and a resale registration statement is due by November 30, 2026.
Post Holdings said its Senior Vice President and Chief Accounting Officer, Bradly A. Harper, is taking a temporary medical leave, with CFO Matthew J. Mainer serving as interim principal accounting officer. The board also approved an updated Code of Conduct, effective February 1, 2027, that adds new content on areas such as artificial intelligence and cybersecurity while stating it does not waive any provision of the prior code.
Bradly A. Harper, SVP and Chief Accounting Officer, is on temporary medical leave; the filing gives no return date.
Matthew J. Mainer, EVP, CFO and Treasurer, is interim Chief Accounting Officer and principal accounting officer during the leave.
Board approved the New Code on October 15, 2026; it takes effect February 1, 2027 and supersedes the Prior Code.
New Code adds content on artificial intelligence, prediction markets and fraud prevention, and expands topics including cybersecurity and conflicts of interest.
Franklin Financial Services Corporation's board declared a $0.34 per share regular cash dividend for the fourth quarter of 2026. The payout matches the prior quarter and is 3.0% above the $0.33 paid in the fourth quarter of 2025, so shareholders of record on November 6, 2026 will receive a modest increase in their quarterly cash payment.
Dividend: $0.34 per share, unchanged from the third quarter of 2026
Year-over-year increase of 3.0% from $0.33 per share in the fourth quarter of 2025
Record date November 6, 2026; payment date November 25, 2026
WaFd reported fiscal 2026 net income of $255.9 million, up 13% from the prior year, with diluted earnings per share up 22% to $3.21. Fourth-quarter results were weaker than the prior quarter, with net income of $60.0 million, down 9%, as merger costs and a $36 million charge-off weighed on earnings, though asset quality measures improved.
Fiscal 2026 net income was $255.9 million versus $226.1 million in fiscal 2025; diluted EPS was $3.21 versus $2.63.
Fourth-quarter diluted EPS was $0.76, down from $0.84 in the June 2026 quarter and up from $0.72 a year earlier.
Non-performing assets fell to $86 million, or 0.32% of total assets, from $136 million, or 0.49%, at June 30, 2026, after a $53 million loan relationship was resolved with a $36 million charge-off.
Fourth-quarter non-interest expense included $6 million in merger-related costs tied to the EverBank merger announced September 7, 2026.
Terra Innovatum Global N.V. dismissed KPMG Accountants N.V. as its independent auditor, effective October 12, 2026, and intends to engage MaloneBailey, LLP for fiscal 2026. The company says the change was not due to any disagreement with KPMG, but the filing notes material weaknesses in internal control over financial reporting that have not been remediated.
Audit Committee dismissed KPMG on October 9, 2026, effective October 12, 2026.
KPMG's report on fiscal 2025 financial statements contained no adverse opinion, disclaimer, or qualification.
Filing cites material weaknesses in internal control disclosed in the 2025 Form 10-K and the June 30, 2026 Form 10-Q, which have not been remediated.
MaloneBailey previously audited the company from April 29, 2025 to January 15, 2026; engagement is subject to client acceptance procedures.
Alliance Entertainment's Compensation Committee approved a raise in the annual base salary of Chief Financial Officer Amanda Gnecco to $350,000, effective October 1, 2026, up from $247,200. The filing also sets her prorated fiscal 2027 target bonus at $81,075, a routine compensation change with no stated effect on company results.
CFO Amanda Gnecco's annual base salary rises to $350,000 from $247,200, effective October 1, 2026.
Her prorated target annual bonus for the fiscal year ending June 30, 2027, is $81,075.
The Compensation Committee authorized the change on October 12, 2026; the 8-K was dated October 16, 2026.
Lucid Diagnostics received a Nasdaq notice on October 12, 2026, saying its common stock closed below the $1 minimum bid price for 30 consecutive business days through October 9, 2026. The company has until April 12, 2027 to regain compliance, and Nasdaq says the listing is not affected at this time, so shareholders can keep trading the stock under LUCD.
Nasdaq notice dated October 12, 2026 cites a closing bid price below $1 for 30 consecutive business days through October 9, 2026
Compliance period runs 180 calendar days, until April 12, 2027, and requires at least $1 for ten consecutive business days
Nasdaq says the notice has no effect on the listing now; common stock continues to trade as LUCD
Arrive AI Inc. said its independent auditor, Stephano Slack LLC, resigned effective October 13, 2026, and that the company engaged M&K CPAS, PLLC the same day to review its September 30, 2026 interim statements and audit fiscal 2026. Stephano Slack's prior audit report on fiscal 2025 included a going-concern explanatory paragraph and cited a material weakness in internal controls that was not fully remediated as of June 30, 2026, which matters for shareholders because it signals ongoing financial reporting and financial viability concerns.
Stephano Slack LLC resigned as auditor effective October 13, 2026; the company describes the separation as amicable.
M&K CPAS, PLLC was engaged on October 13, 2026 for the Q3 2026 review and the fiscal 2026 audit.
Fiscal 2025 audit report included a going-concern paragraph on substantial doubt about the company's ability to continue.
A material weakness tied to embedded derivatives and debt accretion led to 10-Q/A restatements filed April 15, 2026, and was not fully remediated as of June 30, 2026.
PepsiCo issued two tranches of €500 million each: 3.750% senior notes due October 16, 2029, and 4.250% senior notes due October 16, 2035, with the notes issued October 16, 2026. The company received net proceeds of about €994 million, which it will use for general corporate purposes, including repaying commercial paper. The notes are unsecured and rank equally with PepsiCo's other unsecured senior debt, so this is a routine debt financing that the filing does not tie to any change in earnings or guidance.
Two €500 million tranches: 3.750% notes due October 16, 2029 and 4.250% notes due October 16, 2035
Prices to public were 99.953% for the 2029 notes and 99.824% for the 2035 notes
Net proceeds of about €994 million for general corporate purposes, including repaying commercial paper
Joint book-running managers were Deutsche Bank AG, London Branch and HSBC Bank plc
Health In Tech received two Nasdaq letters: one because it is not compliant with independent director and audit committee requirements after a director resigned, and one because its Class A shares closed below $1.00 for 30 consecutive business days. Neither letter has an immediate effect on the listing or trading of the stock, but the company faces cure deadlines and could face delisting if it fails to meet them.
Nasdaq letter dated October 14, 2026 cites non-compliance with independent director and audit committee rules after Sanjay Shrestha resigned on August 10, 2026; the Audit Committee has two members, and the company expects a new independent
Cure period for the board and audit committee rules ends at the earlier of the next annual meeting or August 10, 2027; the company must show compliance by February 8, 2027 if that meeting is held before then
Nasdaq letter dated October 12, 2026 cites a closing bid price below $1.00 for 30 consecutive business days; the company has until April 12, 2027 to regain compliance, which could require a reverse stock split
Bank of Marin and Brandi Campbell, its Executive Vice President and Head of Retail Banking, mutually agreed that her employment would end on October 16, 2026, under a separation agreement effective that day. In exchange for a release of claims, she is entitled to three months' pay in a lump sum and nine months of COBRA premium reimbursement. The filing does not name a successor, so shareholders will need to watch for an update on who will lead retail banking.
Employment termination date: October 16, 2026, mutually agreed by the Bank and Ms. Campbell
Severance: three months' pay in a lump sum, less applicable deductions and withholdings
Benefits: nine months of reimbursement for COBRA premiums, in exchange for a release of claims
Filing signed October 16, 2026 by CFO David Bonaccorso
The fund's board approved a name change to The NXG Cushing Energy Infrastructure Fund and a shift in its 80% investment policy from midstream energy to energy infrastructure, both effective December 18, 2026. The adviser says the fund's portfolio, at 90% energy infrastructure as of October 15, 2026, needs no rebalancing, the ticker stays SRV, and shareholders need not take action.
Name changes to The NXG Cushing Energy Infrastructure Fund effective December 18, 2026; NYSE ticker SRV and CUSIP 231631300 are unchanged.
The 80% policy now covers energy infrastructure investments instead of midstream energy investments, effective December 18, 2026.
As of October 15, 2026, 90% of net assets plus borrowings were in energy infrastructure investments, so no portfolio changes are expected.
No change to the investment adviser or portfolio management personnel; no shareholder action is required.
TOMI Environmental Solutions appointed Niroshan Srirathan, its interim chief financial officer, as permanent CFO, effective immediately, with the board action dated October 11, 2026. He has an annual base salary of $205,000 under an offer letter, and the company says the full letter will be filed as an exhibit to its next periodic report.
Board appointed Niroshan Srirathan, age 39, as permanent Chief Financial Officer on October 11, 2026, effective immediately.
Srirathan previously served as Interim CFO since May 16, 2026, and as Controller since May 4, 2026.
Annual base salary under the offer letter is $205,000.
The filing states no family relationships with directors or executive officers and no reportable related-person transactions.
Global Partners LP and certain subsidiaries entered into an amendment to their credit agreement on October 16, 2026, extending the facility's maturity from March 20, 2028 to October 16, 2031. The $1.0 billion working capital commitment and $500 million revolver commitment were maintained, while a $0 interim commitment replaced the previously extended working capital interim commitment.
Maturity extended from March 20, 2028 to October 16, 2031
Aggregate WC Commitment of $1.0 billion and Aggregate Revolver Commitment of $500 million maintained
Previously extended Aggregate WC Interim Commitment reduced to $0
Certain lenders may assign all or part of their loans and commitments to other lenders
Ocular Therapeutix said its Chief Strategy Officer, Sanjay Nayak, resigned, effective October 16, 2026, to become CEO of a privately held company. The filing does not name a successor or describe any transition arrangements.
Sanjay Nayak notified the company of his resignation on October 14, 2026.
Resignation is effective October 16, 2026.
He is leaving to become Chief Executive Officer of a privately held company, which the filing does not name.
The filing does not name a successor or give financial terms.
Asure Software entered a $115 million senior credit facility with MUFG Bank on October 15, 2026, drawing the full $85.0 million term loan at closing and using proceeds to repay about $62.6 million owed under its MidCap credit agreement. The company also bought payroll processing assets from a southeastern US seller for $26.5 million, paying partly in newly issued common stock, which adds new debt and dilutes existing holders slightly.
$85.0 million term loan drawn October 15, 2026; $10.0 million revolver and $20.0 million delayed-draw term loan remain undrawn
Interest at Term SOFR plus 3.00%, initial three-month rate of 7.04249%; principal payments begin April 1, 2027, with maturity October 15, 2031
Paid $62.6 million to MidCap to retire the prior credit agreement and note, including $2.4 million in prepayment and termination fees
Acquisition price of $26.5 million included $13.5 million cash, a $3.0 million note, and 1,206,141 shares valued at $10.0 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.